^
    Back
    Association details:
    Biomarker:OSBPL1A overexpression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Cell Int
    Title:

    Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer

    Published date:
    02/25/2021
    Excerpt:
    Clinically, patients with advanced CRC and high ORP-1 expression exhibited a longer progression-free survival time when they were treated with anti-EGFR therapy than those with low ORP-1 expression.
    DOI:
    10.1186/s12935-021-01829-8